Signal transduction and targeted therapy
Jun 15, 2025
Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality....
European journal of nuclear medicine and molecular imaging
Jun 2, 2025
PURPOSE: To develop and validate a novel nomogram combining multi-organ PET metabolic metrics for major pathological response (MPR) prediction in resectable non-small cell lung cancer (rNSCLC) patients receiving neoadjuvant immunochemotherapy.
International journal of molecular sciences
Jun 1, 2025
Multispecific antibodies have redefined the immunotherapeutic landscape in hematologic malignancies. Bispecific antibodies (BsAbs), which redirect cytotoxic T cells toward malignant targets via dual antigen engagement, are now established components ...
BACKGROUND: Accurate preoperative prediction of major pathological response or pathological complete response after neoadjuvant chemo-immunotherapy remains a critical unmet need in resectable non-small-cell lung cancer (NSCLC). Conventional size-base...
Bladder cancer is the fourth most common malignant tumor in men, with limited therapeutic biomarkers and heterogeneous responses to immunotherapy. Disulfide bond-driven cell death has emerged as a critical regulator of tumor progression and immune mi...
Non-small cell lung cancer (NSCLC) constitutes over 80% of lung cancer cases and remains a leading cause of cancer-related mortality worldwide. Despite the advent of immune checkpoint inhibitors, their efficacy is limited to 27 to 45% of patients. Id...
Neoantigens have emerged as ideal targets for personalized cancer immunotherapy. We depict the pan-cancer peptide atlas by comprehensively collecting immunopeptidomics from 531 samples across 14 cancer and 29 normal tissues, and identify 389,165 cano...
BACKGROUND: Immune Checkpoint Inhibitor-related Pneumonitis (CIP) exhibits high morbidity and mortality rates in the real world, often coexisting with pneumonia, particularly after immunochemotherapy. We aimed to develop and validate a non-invasive n...
Hepatocellular carcinoma (HCC) is an aggressive cancer with limited biomarkers for predicting immunotherapy response. Recent advancements in large language models (LLMs) like GPT-4, GPT-4o, and Gemini offer the potential for enhancing clinical decisi...
International journal of molecular sciences
May 7, 2025
Precise modulation of the cell cycle via electromagnetic (EM) control presents a groundbreaking approach for cancer therapy, especially in the development of personalized treatment strategies. EM fields can precisely regulate key cellular homeostatic...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.